Table 1.
Baseline Characteristics of the 2 Arms.
| Characteristic | Arm A | Arm B | |
|---|---|---|---|
| No. of patients | 109 | 110 | |
| Age, years | 0.7266 | ||
| Median | 56.0 | 58.0 | |
| Range | 49–62 | 50–63 | |
| Female gender, n(%) | 88 (80.7) | 83 (75.5) | 0.345 |
| Smoking status, n(%) | 1 | ||
| Former smoker | 1(0.9) | 1(0.9) | |
| Never smoker | 108 (99.1) | 109 (99.1) | |
| Pathology, n(%) | 0.2123 | ||
| Adenocarcinoma | 105 (96.3) | 109 (99.1) | |
| Adenosquamous carcinoma | 4 (3.7) | 1 (0.9) | |
| ECOG performance status, n(%) | 0.6278 | ||
| 0 | 35 (32.1) | 32 (29.1) | |
| 1 | 74 (67.9) | 78 (70.9) | |
| Current disease stage, n(%)* | 0.3079 | ||
| IIIB | 6 (5.5) | 10 (9.1) | |
| IV | 103 (94.5) | 100 (90.9) | |
| Brain metastasis | 0.1716 | ||
| Yes | 16 (14.7) | 24 (21.8) |
NOTE: The ITT dataset was used to generate this table. Arm A: gemcitabine + carboplatin + gefitinib; Arm B: gemcitabine + carboplatin. *American Joint Committee on Cancer (AJCC) stage. Abbreviation: ECOG = Eastern Cooperative Oncology Group.